Shopping Cart
- Remove All
Your shopping cart is currently empty
TDI-10229
Catalog No. T64355Cas No. 2810887-45-5
TDI-10229 is a potent and orally available inhibitor of soluble adenylyl cyclase (sAC, ADCY10), displaying nanomolar inhibition of sAC in both biochemical and cellular assays (IC50 = 195 nM). TDI-10229 exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compound.
TDI-10229
Catalog No. T64355Cas No. 2810887-45-5
TDI-10229 is a potent and orally available inhibitor of soluble adenylyl cyclase (sAC, ADCY10), displaying nanomolar inhibition of sAC in both biochemical and cellular assays (IC50 = 195 nM). TDI-10229 exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compound.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $35 | In Stock | |
| 5 mg | $168 | In Stock | |
| 10 mg | $248 | In Stock | |
| 25 mg | $455 | In Stock | |
| 50 mg | $683 | In Stock | |
| 100 mg | $987 | In Stock | |
| 200 mg | $1,330 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $186 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "TDI-10229"
Bithionol
Actamer
T083097-18-7
Bithionol (Actamer), formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967.
- $50
Size
QTY
Torbafylline
T67965105102-21-4In house
Torbafylline, a xanthine derivative, is a phosphodiesterase (PDE) inhibitor that attenuates burn-induced protein hydrolysis in rat skeletal muscle through activation of the PDE4/cAMP/EPAC/PI3K/Akt pathway, and inhibits the enhanced ubiquitin-proteasome-dependent protein hydrolysis in skeletal muscle of cancer- and sepsis-prone rats.
- $130
Size
QTY
2-PCCA hydrochloride
2-PCCA hydrochloride（1609624-97-6 Free base)
T806661609563-70-3In house
2-PCCA hydrochloride, a racemate, is a potent and selective GPR88 receptor agonist showing inhibition of GPR88-mediated cAMP production in HEK293 cells with an EC50 value of 116 nM.
- $195
Size
QTY
I942
I-942, I 942
T24154868145-09-9
I942 is a novel, selective ACyclic nucleotide (NCN) EPAC1 agonist that activates exchange proteins to regulate inflammatory gene expression in human umbilical blood tubes and inhibit pro-inflammatory cytokine signaling associated with cardiovascular disease.
- $96
Size
QTY
Adenosine receptor A1 antagonist 5
T2246685872-53-3In house
Adenosine receptor A1 antagonist 5 acts as an adenosine antagonist, is an oxypurine, acts as an insecticide and pest control agent, and has an inhibitory effect on elevated blood pressure.
- $98
Size
QTY
HJC0350
T6536885434-70-8
HJC0350 is an effective and specific EPAC2 inhibitor (IC50: 0.3 μM), and no inhibition of Epac1.
- $30
Size
QTY
GAT211
GAT-211, GAT 211, AZ-4, AZ4, AZ 4
T27405102704-40-5
GAT211 (AZ-4) is a selective and potent cannabinoid 1 receptor (CB1R) orthosteric modulator (PAM) with high affinity for cAMP and β-arrestin2.GAT211 has IOP-lowering and antipsychotic effects and can be used in the study of epilepsy.
- $30
Size
QTY
UNC0006
UNC-0006, UNC 0006
T290611354030-14-0In house
UNC0006 is a beta-inhibitory protein biased D(2)R ligand, and is also an antagonist of G(i)-regulated cAMP production and a partial agonist of D(2)R/beta-arrestin-2 interaction. It has antipsychotic activity and is used in the study of neurological disorders.
- $293
Size
QTY
ESI-05
NSC 116966
T152475184-64-5
ESI-05 (NSC-116966) is a specific EPAC2 (exchange protein directly activated by cAMP 2) antagonist (IC50: 0.4 μM). ESI-05 inhibits cAMP-mediated activation of EPAC2, as well as EAPC2, mediated Rap1 activation.
- $33
Size
QTY
HJC0197
T154851383539-73-8
HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 is an effective exchange protein. Which straightly activated by cAMP (Epac) antagonist (IC50=5.9 μM for Epac2).
- $32
Size
QTY
MRE3008F20
T16132252979-43-4In house
MRE3008F20 is a species-selective and potent adenosine A3 receptor (AA3R) antagonist that inhibits Cl-IB-MECA-induced cAMP production and can be used in glaucoma and asthma studies.13483-88-88-9
- $64
Size
QTY
ESI-09
Cited
T2244263707-16-0
ESI-09 is a new-typel noncyclic nucleotide EPAC antagonist.The IC50 values of ESI-09 for EPAC1 and EPAC2 is 3.2 and 1.4 μM, respectively.
- $35
Size
QTY
CitedSelect Batch
Purity:97.77%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | TDI-10229 is a potent and orally available inhibitor of soluble adenylyl cyclase (sAC, ADCY10), displaying nanomolar inhibition of sAC in both biochemical and cellular assays (IC50 = 195 nM). TDI-10229 exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compound. |
| In vitro | TDI-10229 inhibits human 4-4 cells with an IC50 of 92 nM for[2]. |
| In vivo | TDI-10229 (20 mg/kg; p.o.) treatment in mouse shows the AUC, Cmax, and MRT were 94 μg h/mL, 15.5 μM, and 3.95 hours, respectively[2]. |
| Molecular Weight | 313.78 |
| Formula | C16H16ClN5 |
| Cas No. | 2810887-45-5 |
Storage & Solubility Information
| Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 112.5 mg/mL (358.5 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy TDI-10229 | purchase TDI-10229 | TDI-10229 cost | order TDI-10229 | TDI-10229 chemical structure | TDI-10229 in vivo | TDI-10229 in vitro | TDI-10229 formula | TDI-10229 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.